Glenmark Life Sciences IPO

Glenmark Life Sciences IPO Date, Price band, Details

Spread the love

Glenmark Life Sciences IPO will open for subscription from 27 July 2021. The company aims for an issue size of ₹1,513.60 Crore through this IPO.

Glenmark Life Sciences Limited

Incorporated in 2011, Glenmark Life Sciences is the leading manufacturer of Active Pharmaceutical Ingredients (APIs). The company develops, manufactures, and supplies high-quality APIs for cardiovascular disease (CVS), central nervous system disease (CNS), pain management, and diabetes, gastrointestinal disorders, anti-infectives, and other therapeutic areas. It further operates in Contract Development and manufacturing operations (CDMO) to offer services to specialty Pharmaceutical companies.

Its products are being sold in India and also exported to multiple countries i.e. Europe, North America, Latin America, Japan, etc. Currently, it has 4 manufacturing facilities at Ankleshwar and Dahej in Gujarat and Mohol and Kurkumbh in Maharashtra State with an aggregate annual installed capacity of 725.8 KL as of December 31, 2020.

Also read: IPO List 2021: a complete list of IPOs in 2021

Objects of the Issue

  • To make payment of outstanding purchase consideration to the promoter for the spin-off of the API business from the promoter into the company.
  • To finance capital expenditure requirements.
  • For general corporate purposes.

Competitive strengths

  • Leading manufacturer of selected specialized APIs for chronic therapeutic areas like CVS, CNS, diabetes, and pain management.
  • Export products in Europe, Latin America, North America, Japan, and the rest of the world.
  • A strong relationship with leading global generic companies.
  • Proven track record of strong financial performance.
  • High-quality product manufacturing with R&D infrastructure.

Basic details about the company

Full nameGlenmark Life Sciences Limited IPO
IndustryPharmaceuticals & Drugs

Dates to remember

IPO Open27 July 2021
IPO Close29 July 2021
Basis of Allotment03 Aug 2021
Refunds date04 Aug 2021
Credit to Demat Account05 Aug 2021
 Listing Date06 Aug 2021

IPO details

Issue typeBook Building
IPO issue size₹1,513.60 Crore
Fresh Issue₹1,060 Cr
Offer for sale₹453.60 Cr
Face value₹02 Per Equity Share
Price band₹695 to ₹720 per equity share
Retail Allocation35%
Lot size20 Shares
Minimum application1 Lot20 Shares
Maximum application13 Lots-260
Minimum application amount₹14,400
Maximum application amount₹187,200
Listing ExchangeBSE & NSE

Company Financials

ParticularsFor the year/period ended (₹ in million)
Total Assets19,970.7517,256.0414,753.95
Total Revenue18,859.7615,493.038,868.65
Profit After Tax3,515.813,130.981,955.92

Valuation of Glenmark Life Sciences (as of FY2020)

Earnings Per Share (EPS)₹32.61
Price/Earnings (PE ratio)21.31 – 22.08
Return on Net Worth (RONW)46.71%
Net Asset Value (NAV)₹69.82 per share

Company Promoters

  • Glenmark Pharmaceuticals Limited

Lead Managers

  • BoA Merrill Lynch
  • BOB Capital Markets Limited
  • DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd)
  • Goldman Sachs (India) Securities Private Limited
  • Kotak Mahindra Capital Company Limited
  • SBI Capital Markets Limited

Glenmark Life Sciences IPO Allotment Status

Glenmark Life Sciences IPO allotment will be available on KFin Technologies’ website.

Click on this link to get allotment status.

Glenmark Life Sciences IPO Registrar

KFintech Private Limited
KFintech, Tower-B, Plot No 31 & 32,
Financial District, Nanakramguda, Gachibowli,
Hyderabad, Telangana India – 500 032.
Phone: 04067162222, 04079611000

Company Contact Information

Glenmark Life Sciences Limited
Plot No. 170-172, Chandramouli Industrial Estate,
Mohol Bazarpeth, Solapur 413 213,
Phone: +91 2189 234456/ +91 2189

Final thoughts

Glenmark Life Sciences IPO is going to hit Dalal street soon. applying for IPO is purely a personal choice. study well about the company and do subscribe if you are feeling good about the company. I hope this post will give you enough details to make a fundamental study of the company. learn well and make a wise decision.

Happy Investing

Spread the love

Leave a Comment

Your email address will not be published. Required fields are marked *